Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies

Elizabeth Sakach,Ruth O'Regan,Jane Meisel,Xiaoxian Li

Clinical Breast Cancer（2021）

引用 10|浏览17

暂无评分

摘要

Triple negative breast cancer (TNBC) represents 15% to 20% of all primary breast cancers and is the most aggressive subtype of breast cancer. There has been rapid progress in targeted therapy and biomarker development to identify the optimal treatments for TNBC.

查看译文

关键词

PD-L1,PARP inhibitor,AKT inhibitor,antibody-drug conjugate,androgen receptor inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要